| Issue Date | Title | Author(s) |
| 2023 | Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China | Hua, Rui; Kong, Fei; Li, Guangming; Wen, Xiaofeng; Zhang, Yuexin; Yang, Xingxiang; Meng, Chenxin; Xie, Wen; Jiang, Yongfang; Wang, Xiaozhong; Han, Xueji; Huang, Yan; Mao, Qing; Wang, Jiefei; Guan, Yujuan; Chen, Jiayu; Ma, Yingjie; Xiong, Qingfang; Ma, Hong; Yan, Xuebing; Rao, Huiying; Zhao, Yingren; Sun, Tong; Zhu, Liying; Mao, Xiaorong; Lian, Jianqi; Deng, Guojiong; Xin, Yongning; Wang, Yifei; Ye, Yinong; Xu, Bin; Gao, Hainv; Tan, Youwen; Li, Dongliang; Yang, Dongliang; Su, Minghua; Zhang, Xiaomeng; Min, Jie; Shi, Xinsheng; Wei, Lai; Niu, Junqi |
| 2019 | All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Ji-Dong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojong; Zhang, Quan; Hu, Peng; Wang, Fu-Sheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| 6-Apr-2021 | Conjunctival Microbiota in Patients With Type 2 Diabetes Mellitus and Influences of Perioperative Use of Topical Levofloxacin in Ocular Surgery | Zhu, Xiangjia; Wei, Ling; Rong, Xianfang; Zhang, Yinglei; Zhang, Qian; Wen, Xiaofeng; He, Wenwen; Zhang, Keke; Chen, Feng; Wei, Lai; Lu, Yi |
| 1-Apr-2021 | COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas | Ren, Xianwen; Wen, Wen; Fan, Xiaoying; Hou, Wenhong; Su, Bin; Cai, Pengfei; Li, Jiesheng; Liu, Yang; Tang, Fei; Zhang, Fan; Yang, Yu; He, Jiangping; Ma, Wenji; He, Jingjing; Wang, Pingping; Cao, Qiqi; Chen, Fangjin; Chen, Yuqing; Cheng, Xuelian; Deng, Guohong; Deng, Xilong; Ding, Wenyu; Feng, Yingmei; Gan, Rui; Guo, Chuang; Guo, Weiqiang; He, Shuai; Jiang, Chen; Liang, Juanran; Li, Yi-min; Lin, Jun; Ling, Yun; Liu, Haofei; Liu, Jianwei; Liu, Nianping; Liu, Shu-Qiang; Luo, Meng; Ma, Qiang; Song, Qibing; Sun, Wujianan; Wang, GaoXiang; Wang, Feng; Wang, Ying; Wen, Xiaofeng; Wu, Qian; Xu, Gang; Xie, Xiaowei; Xiong, Xinxin; Xing, Xudong; Xu, Hao; Yin, Chonghai; Yu, Dongdong; Yu, Kezhuo; Yuan, Jin; Zhang, Biao; Zhang, Peipei; Zhang, Tong; Zhao, Jincun; Zhao, Peidong; Zhou, Jianfeng; Zhou, Wei; Zhong, Sujuan; Zhong, Xiaosong; Zhang, Shuye; Zhu, Lin; Zhu, Ping; Zou, Bin; Zou, Jiahua; Zuo, Zengtao; Bai, Fan; Huang, Xi; Zhou, Penghui; Jiang, Qinghua; Huang, Zhiwei; Bei, Jin-Xin; Wei, Lai; Bian, Xiu-Wu; Liu, Xindong; Cheng, Tao; Li, Xiangpan; Zhao, Pingsen; Wang, Fu-Sheng; Wang, Hongyang; Su, Bing; Zhang, Zheng; Qu, Kun; Wang, Xiaoqun; Chen, Jiekai; Jin, Ronghua; Zhang, Zemin |
| 2019 | Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C | Wei, Lai; Shang, Jia; Ma, Yuanji; Xu, Xiaoyuan; Huang, Yan; Guan, Yujuan; Duan, Zhongping; Zhang, Wenhong; Gao, Zhiliang; Zhang, Mingxiang; Li, Jun; Jia, Jidong; Yang, Yongfeng; Wen, Xiaofeng; Wang, Maorong; Jia, Zhansheng; Ning, Bo; Chen, Yongping; Qi, Yue; Du, Jie; Jiang, Jianning; Tong, Lixin; Xie, Yao; Wu, Jinzi J. |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
| 2019 | Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China | Xu, Xiaoyuan; Feng, Bo; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; Anl, Ping; Gong, Guozhong; Liu, Huimin; Nine, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, Fusheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi J.; Wei, Lai |
| 2019 | THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL | Wei, Lai; Xu, Xiaoyuan; Zheng, Sujun; Guan, Yujuan; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qing; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang, Sr.; Chen, Liang; Ye, Yinong, Sr.; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| Jul-2021 | SH229 plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study | Hua, Rui; Kong, Fei; Wen, Xiaofeng; Yang, Xingxiang; Meng, Chenxin; Jiang, Yongfang; Xie, Wen; Wang, Xiaozhong; Han, Xueji; Huang, Yan; Wang, Jiefei; Mao, Qing; Guan, Yujuan; Chen, Jiayu; Ma, Yingjie; Ma, Hong; Xiong, Qingfang; Yan, Xuebing; Rao, Huiying; Zhao, Yingren; Sun, Tong; Mao, Xiaorong; Lian, Jianqi; Zhu, Liying; Xin, Yongning; Deng, Guojiong; Wang, Yifei; Xu, Bin; Gao, Hainv; Tan, Youwen; Ye, Yinong; Li, Dongliang; Yang, Dongliang; Su, Minghua; Li, Cheng; Shen, Xian; Wu, Qiong; Zhang, Xian; Wang, Zhiqiang; Zhao, Liwen; Zhang, Yuexin; Li, Guangming; Niu, Junqi |
